"Proteasome Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the function or proteolytic action of the PROTEASOME.
| Descriptor ID |
D061988
|
| MeSH Number(s) |
D27.505.519.389.745.705
|
| Concept/Terms |
Proteasome Inhibitors- Proteasome Inhibitors
- Inhibitors, Proteasome
- Proteasome Inhibitor
- Inhibitor, Proteasome
- Proteasome Endopeptidase Complex Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Proteasome Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Proteasome Inhibitors".
This graph shows the total number of publications written about "Proteasome Inhibitors" by people in this website by year, and whether "Proteasome Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 4 | 5 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 3 | 4 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 4 | 4 |
| 2020 | 3 | 2 | 5 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proteasome Inhibitors" by people in Profiles.
-
Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data. Cancer Treat Res Commun. 2025; 43:100921.
-
Effectiveness of combined plasma cell therapy and costimulation blockade based desensitization regimen in heart transplant candidates. Clin Transplant. 2024 02; 38(2):e15249.
-
Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation. Cancer Res Commun. 2022 12; 2(12):1693-1710.
-
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 2022 Dec; 9(12):e897-e905.
-
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 02 20; 41(6):1265-1274.
-
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. Clin Lymphoma Myeloma Leuk. 2022 05; 22(5):297-304.
-
Reducing treatment toxicity in Waldenstr?m macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676.
-
Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.
-
Management of Waldenstr?m macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379.
-
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 10; 21(10):1317-1330.